OBJECTIVES: This study aimed to evaluate the causes of initial mitral valve (MV) repair failure, the details of reoperation and the longterm outcomes of mitral valve re-repair (Re-MVP).
INTRODUCTION
Mitral valve (MV) repair for mitral regurgitation (MR) is recommended in qualified centres [1] . Many qualified centres have reported excellent outcomes after MV repair, indicating that MV repair has low morbidity and mortality and is a reproducible and durable surgical technique [2] [3] [4] [5] . However, the incidence of reoperation after initial MV repair failure is 4.5-8% at 10 years [2] [3] [4] [5] , and reoperation occurs at a linearized hazard rate of 0.5-1.5% per year [6] . To improve the outcome of initial MV repair, it is important to analyse the causes and mechanisms of MV repair failure. However, only a few reports have investigated the mechanisms of initial MV repair failure [6, 7] . The aims of this study were to evaluate the causes of initial MV repair failure, the details of the reoperation and the long-term outcomes of these patients.
MATERIALS AND METHODS

Patients and study design
A total of 1574 patients underwent MV repair for MR due to degenerative disease between October 1991 and December 2015 at the Sakakibara Heart Institute. Leaflet prolapse affected the posterior leaflet in 822 (52%) patients, the anterior leaflet in 276 (18%) patients and both leaflets in 476 (30%) patients. For these patients, we performed leaflet resection in 1156 (73%) patients, neochordae (NC) implantation in 1069 (68%) patients and ring annuloplasty in 1553 (99%) patients. Among these patients, 86 patients underwent 86 reoperations for initial MV repair failure. Patients who underwent initial MV repair at other hospitals were excluded. We included only degenerative MV disease as the primary disease in this study and excluded rheumatic, infectious and congenital valve diseases.
First, we analysed the details of the initial operation, indication for reoperation, cause of repair failure, reoperation data and longterm outcomes including survival and freedom from reoperation. Second, we classified the patients into 2 groups based on the cause of failure (procedure-related versus valve-related) and analysed the differences between these groups. Procedure-related failure included leaflet suture dehiscence, ring detachment, NC complications (such as NC maladjustment and NC rupture) and left ventricular pseudoaneurysm. We included left ventricular pseudoaneurysm complication in procedure-related failure because the causes of pseudoaneurysm were due to the injury of the left ventricle muscle by an annuloplasty stitch. Valve-related failure included progression of degenerative change (PD), new lesion development and infective endocarditis (IE). The causes of MV repair failure were determined by an echocardiogram and the surgeon's observation during the operation.
Our institutional review board approved this study and waived the requirement for informed consent. All data were collected prospectively and reviewed retrospectively from the medical chart of each patient during routine follow-up visits to the outpatient clinic or by telephone interview. The last follow-up was conducted between August 2016 and October 2016. The mean follow-up period was 76.3 ± 55.0 months after reoperation, and the follow-up rate was 100%. In the re-repair patients, postdischarge transthoracic echocardiography was performed in 20 patients at least once. The median echocardiographic follow-up period was 24.0 (interquartile range 12.0-61.0) months.
Surgical protocols
The initial operation was performed via a median sternotomy in 80 (93%) patients and via a right minithoracotomy in 6 (7%) patients. Reoperation was performed via the median sternotomy in 85 (99%) patients and via the right minithoracotomy in 1 (1%) patient. We dissected the adhesion and established a cardiopulmonary bypass with the ascending aorta and bicaval venous drainage. After cross-clamping, we accessed the MV via the superior trans-septal approach. In all cases, we evaluated the MV thoroughly and analysed the reasons for failure. When necessary, we removed the annuloplasty ring to analyse the valve. Our standard strategy for reoperation of initial MV repair failure has been the mitral valve re-repair (Re-MVP). However, if the MV was irreparably damaged on intraoperative examination (e.g. loss of valve leaflet pliability, leaflet shrinkage or extended infection), MV replacement was performed. The standard procedures for the MV repair were triangular or rectangular resection for the posterior leaflet lesions and polytetrafluoroethylene NC implantation for the anterior leaflet lesions [8] [9] [10] . If the posterior leaflet volume was not sufficient to resect, we performed NC implantation for the posterior leaflet. These procedures were also adapted for the Re-MVP. When suture dehiscence or ring detachment was observed, we directly resutured if the valve leaflet was pliable. If not pliable, we reinforced it with the autologous pericardium. If the repaired site was hard and difficult to obtain smooth coaptation with the surrounding leaflet, we used the autologous pericardium to cover it, regardless of whether the lesion was anterior or posterior. In left ventricular pseudoaneurysm cases, we covered the hole detected in the left ventricle with a bovine pericardium patch. Each MV repair was evaluated by transoesophageal echocardiography in the operating room. MV replacement was performed with a commercially available bioprosthesis or mechanical valve. We chose the mechanical valve for patients <65 years in nearly all cases. In 1 case, we used an MV made of autologous pericardium [11, 12] .
Statistical analyses
All data analyses were performed with JMP 11.0 software (SAS Institute Inc., Cary, NC, USA). Data were expressed as mean ± standard deviation if normally distributed and median and interquartile range if not normally distributed for continuous variables and as numbers (percentages) for categorical variables. Statistical comparison between the 2 groups was tested with the unpaired t-test or the non-parametric Wilcoxon test for continuous variables and the v 2 test or the Fisher's exact test for categorical variables. Longterm survival and freedom from MV reoperation were analysed using the Kaplan-Meier method and log-rank test. A P-value of < _0.05 was considered statistically significant.
RESULTS
Initial mitral valve repair
The initial MV repair data are listed in Table 1 . The mean age of the patients at the initial operation was 54.5 ± 14.2 years. Thirtyone (36%) patients were female. Mean MR grade before the initial operation was 3.8 ± 0.4 (none: 0, trivial: 1, mild: 2, moderate: 3 and severe: 4). The primary valve disease was degenerative disease in all patients. Leaflet prolapse affected the bilateral mitral leaflets in 37 (43%) patients, the anterior mitral leaflet in 30 (35%) patients and the posterior mitral leaflet in 19 (22%) patients. In segmental leaflet prolapse, A1 was detected in 25 (29%) patients, A2 in 50 (59%) patients, A3 in 46 (54%) patients, Ac in 5 (6%) patients, P1 in 11 (13%) patients, P2 in 30 (35%) patients, P3 in 28 (33%) patients and Pc in 7 (8%) patients.
Techniques used at initial MV repair are listed in Tables 2 and 3 . In the anterior mitral leaflet or posterior mitral leaflet group, most of the techniques employed were NC implantation (27 patients, 55%) and resection (13 patients, 27%). In the bilateral mitral leaflet group, the main technique employed was resection combined with NC implantation, which was performed in 26 (70%) patients. 
Pre-reoperative background
Mean age at the time of reoperation was 59.1 ± 14.7 years. Median duration from the initial operation to reoperation was 47.5 (interquartile range 4.8-85.8) months. The indications for reoperation were recurrent MR alone in 59 (69%) patients, haemolysis combined with MR in 15 (17%) patients, IE combined with recurrent MR in 8 (9%) patients, mitral stenosis in 2 (2%) patients and left ventricular pseudoaneurysm in 2 (2%) patients (Tables 2 and 3) . We had no cases of systemic anterior movement for reoperation in this study. Eight (9%) patients underwent reoperation during hospitalization for the initial operation due to suture dehiscence in 3 patients, IE in 2 patients, left ventricular pseudoneurysm in 2 patients and new lesion in 1 patient.
Reoperation data
We performed Re-MVP in 23 (27%) patients and redo MV replacement in 63 (73%) patients. A mechanical valve was used in 47 patients, bioprosthesis in 15 patients and the MV made of autologous pericardium in 1 patient. In the Re-MVP group, intraoperative transoesophageal echocardiography revealed none or trivial MR in 22 (91%) patients and mild in 1 (9%) patient. The concomitant procedures included tricuspid valve annuloplasty in 25 (29%) patients, aortic valve replacement in 6 (7%) patients, coronary artery bypass grafting in 2 (2%) patients, maze procedure in 2 (2%) patients, pulmonary vein isolation in 2 (2%) patients, ascending aortic replacement in 1 (1%) patient, valvesparing aortic root replacement in 1 (1%) patient and tricuspid valve replacement in 1 (1%) patient.
We divided all patients into the valve-related and the procedure-related failure groups based on the cause of initial MV repair failure. Of the 86 patients, valve-related failure included PD in 44 (51%) patients, new lesion in 8 (9%) patients, IE in 8 (9%) patients and PD combined with new lesion in 1 (1%) patient. Procedure-related failure included NC complications in 9 (11%) patients, leaflet suture dehiscence in 6 (7%) patients, ring detachment in 3 (4%) patients and left ventricular pseudoaneurysm in 2 (2%) patients. Both failure included PD combined with NC complications in 2 (2%) patients, PD combined with ring detachment in 2 (2%) patients and PD combined with suture dehiscence in 1 (1%) patient (Tables 2 and 3) .
When we compared the Re-MVP group with the redo MV replacement group, the Re-MVP patients were significantly younger than redo MV replacement patients (P < 0.001, Table 4 ). However, there were no differences in ejection fraction, operation time and cross-clamp time. Re-MVP was performed significantly more frequently in procedure-related failure than in valve-related failure (P < 0.001). The mean duration from the initial operation to reoperation in Re-MVP was significantly shorter than in MV replacement (P = 0.021, Table 4 ).
The surgical techniques used for Re-MVP are also listed in Tables 2 and 3 .
Early outcomes
Operative mortality was 1.2% (1 of 86 patients). The cause of death was uncontrollable bleeding after MV replacement for left ventricular pseudoaneurysm. There were no deaths after Re-MVP.
The postoperative morbidities included pneumonia in 6 patients, stroke in 3 patients, renal failure in 2 patients and mediastinitis in 1 patient. There were no differences between the Re-MVP group and the redo MV replacement group in operative mortality and postoperative morbidities.
Long-term survival
There were 14 deaths during the mean follow-up period of 76.3 ± 55.0 months. Thirteen patients in redo MV replacement died, and 1 patient in Re-MVP died. The cause of death among the redo MV replacement patients was pneumonia in 3 patients, congestive heart failure in 2 patients, stroke in 2 patients, IE in 1 patient, myocardial infarction in 1 patient, malignant tumour in 1 patient, arrhythmia in 1 patient and unknown in 2 patients; 1 Re-MVP patient died from aplastic anaemia. Overall actuarial survival rates were 86.8% at 5 years and 86.8% at 10 years in all patients (Fig. 1) . Survival rates in the redo MV replacement group were 82.0% at 5 years and 82.0% at 10 years while that of the Re-MVP group was 100% at 10 years (log rank = 0.039).
Late third mitral surgery
One patient (1 of 23, 4%) who underwent Re-MVP, subsequently required MV replacement due to haemolysis. The patient underwent third mitral surgery at 1 month after reoperation. After Re-MVP, freedom from third mitral surgery at both 5 and 10 years was 95.7% (Fig. 2) . Two (2 of 63, 3%) patients who underwent redo MV replacement subsequently required a third mitral surgery due to structural valve deterioration in one patient and left ventricular pseudoaneurysm in the other patient. After second MV replacement, freedom from reoperation at 5 and 10 years were 98.3% (Fig. 2) . There was no significant difference between the Re-MVP and the redo MV replacement groups in the third mitral surgery (log rank = 0.94). Transthoracic echocardiographic studies of the re-repaired MV revealed none or trivial MR in 15 patients, mild in 4 patients, moderate in 1 patient and severe in 1 patient at the last followup. The patient with severe MR was carefully followed up because he did not have clinical symptoms.
DISCUSSION
In this study, we reported the details of initial MV repair, the causes of failure, the techniques used to perform Re-MVP and the long-term outcomes. There were only a few studies reporting these detailed data. The association of initial repair, cause of failure and re-repair technique are compiled and listed in Tables 2 and 3 . To the best of our knowledge, this is the first study reporting these data.
Mechanisms of mitral valve regurgitation after initial mitral valve repair
In our study, approximately 71% of the failures were valverelated and 23% were procedure-related. Moreover, more than half of the procedure-related failures involved technical failures such as suture dehiscence and NC complications. Our findings are similar to previous reports, in which the proportion of procedure-related failure was reported to be 40-60% [6, 7, 13, 14] . Dumont et al. [14] reported on reoperation after MV repair in 188 patients, with a proportion of procedure-related failure of about 50%; this included valve-related failure in 109 patients (PD in 100) and procedure-related failure in 96 patients (suture dehiscence in 40 patients, haemolysis in 21, chordae complication in 20 and systolic anterior motion in 20) [14] .
What is a good indication for mitral valve re-repair?
The Re-MVP rate widely differs across institutions. Several studies have reported the rates of Re-MVP after initial MV repair failure ranging from 21% to 85% [6, 7, [13] [14] [15] . There are many factors that influence the decision whether or not Re-MVP should be performed. It is not clearly understood what level of valve failure is suitable for Re-MVP. We consider that the cause of mitral valve repair failure might have a great impact on the successful re-repair. Re-MVP is often preferred for patients with procedure-related failure that occurs quickly after initial MV repair [6] . More than half of the cases of procedure-related failure were related to early postoperative technical failure such as suture line dehiscence, NC complications and ring detachment [6, 14, 15] . Re-MVP might be appropriate and relatively feasible in these cases. Anyanwu et al. [15] reported an excellent success rate for Re-MVP of 85%. According to their report, the mode of failure was technical failure in 38% and progression of original disease in 36% [15] .
In contrast, it might be difficult to perform Re-MVP in valverelated failure cases due to PD or IE. Dumont et al. [14] reported that their success rate for Re-MVP was 36%. According to their report, progressive degeneration and endocarditis was the reason for failure in approximately 60%. Our report had similar valve rerepair and valve-related failure rates. In line with our results, Dumont et al. [14] also reported that the median duration from the initial operation to reoperation was significantly shorter in procedure-related failure (19 days) than in valve-related failure (5.4 years). We believe that residual MR might increase the PD gradually over time and make MR worse. In these cases, the MV leaflet loses its pliability and shrinks, leading to difficulty in performing Re-MVP.
How should we re-repair the mitral valve?
Only a few studies have reported on Re-MVP methods [15, 16] . This study analysed the detailed techniques used for Re-MVP. Simple suture dehiscence or maladjustment of NC that has occurred quickly after initial MV repair might be easy to re-repair. In these cases, simple resuture or NC reimplantation might be adequate. However, when the MV has some degenerative changes in the repaired site, it might not be enough to simply re-repair. If these degenerative change sites are left untreated, it might cause tissue redehiscence or inadequate coaptation. To reinforce these sites, we actively used autologous pericardium. The effectiveness of a glutaraldehyde-treated autologous pericardium patch for the MV repair has been reported [16] [17] [18] .
Haemolysis is another cause of MV repair failure. We performed 7 Re-MVPs for haemolysis. Haemolysis mechanisms include a regurgitant jet directly hitting a stiff object such as an annuloplasty ring, a pledget or a suture or the regurgitant jet originating from a small orifice such as a suture dehiscence or ring detachment [19, 20] . Although haemolysis might be resolved by the MV replacement, it may potentially be resolved by using the pericardium to cover the stiff object [21, 22] . We used the pericardium in 3 cases. There are few reports regarding the outcome of Re-MVP for IE, and so it is a difficult topic to discuss.
Long-term outcomes of reoperations for initial mitral valve repair failure
Several studies have demonstrated that MV repair has superior long-term survival compared with that of MV replacement [23] . However, the long-term survival of patients who undergo reoperation for initial MV repair failure is not well known. Dumont et al. [14] reported that the survival of Re-MVP patients at 12 years after the reoperation was significantly better than redo MV replacement patients. Suri et al. [5, 6] reported similar data in 2006. In our series, although the Re-MVP patients were younger, survival of Re-MVP patients was 100% at 5 years while that of redo MV replacement patients was 81.1% at 5 years. Furthermore, Suri et al. [6] reported that Re-MVP was an independent factor for improving survival.
The 10-year freedom from reoperation after remitral valve repair was 95.7% at our institution. The freedom from reoperation after re-repair has been reported to be 94% at 10 years [4] , 93% at 10 years [14] and 95% at 7 years in re-repaired patients and MV replacement patients [16] . The results of this study are acceptable when compared with these previous studies. If the Re-MVP was performed effectively, the duration was good. Although there are concerns regarding Re-MVP failure, we believe that the outcome of re-repair was good enough to justify it being performed, if possible.
LIMITATIONS
This was a single-institution study and not a randomized trial. The selection of Re-MVP or MV replacement was based on the surgeon's judgement. The post-discharge echocardiographic followup was limited and insufficient to describe the course of MR after remitral valve repair. The sample size was too small to analyse the risk factors for long-term survival and re-reoperations.
CONCLUSIONS
Re-MVP was more common in patients with procedure-related failure, which occurred earlier than valve-related failure. If Re-MVP is performed appropriately, re-repair is a feasible option and patient survival is acceptable.
